While traditional induction therapy for newly diagnosed stage 2 myeloma often focuses on combinations of proteasome inhibitors, immunomodulatory drugs, and steroids, these newer immunotherapy classes ...

FDA approves daratumumab for high-risk smoldering multiple myeloma, transforming treatment strategies and enhancing patient ...

Bispecific antibodies target specific cells, offering effective treatment for relapsed/refractory multiple myeloma, with varying side effect profiles. Bispecific antibodies are a type of immunotherapy ...

Bispecific and trispecific antibodies show efficacy in multiple myeloma, moving into earlier lines of therapy.

Blenrep® (belantamab mafodotin) has been registered for use in adults with multiple myeloma who have relapsed or become resistant to first-line ...

Multiple myeloma (MM) is a life-threatening hematological malignancy. High-dose chemotherapy followed by autologous stem cell transplantation is a relatively effective treatment, but disease ...

Multiple myeloma still appears to be an incurable hematological malignancy. One of the reasons is that myeloma cells can be heterogenous and acquire resistance after anti-myeloma treatment.

How Does Sarclisa Work in Multiple Myeloma? Sarclisa is a type of medicine called a monoclonal antibody that is also known as a targeted therapy or an immunotherapy. It works by targeting a specific ...

Hans Lee, MD, MD Anderson Cancer Center, talks about recent advancements in multiple myeloma treatment pathways. At a recent Institute for Value-Based Medicine ® event in Houston, Hans Lee, MD, ...

For the first time in more than a decade, a new frontline treatment for an incurable blood cancer is being added to the ...

Darzalex (daratumumab) is used for treating a blood cancer called multiple myeloma. Darzalex may be used to treat multiple myeloma that has never been treated, is relapsed, meaning the cancer came ...

Multiple myeloma is a rare blood cancer that develops in the plasma cells, which are white blood cells that help you fight ...